Ke Hu

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

Larry K. Kvols, Kjell E. Öberg, Thomas M. O’Dorisio et al. · Endocrine Related Cancer · 2012 · 195 citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

Jianzhen Lin, Xu Yang, Junyu Long et al. · HepatoBiliary Surgery and Nutrition · 2020 · 155 citations · Full text

Medicine, Oncology, Pharmacology +12

Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy

Ke Hu, Weiping Wang, Xiaoliang Liu et al. · Radiation Oncology · 2018 · 149 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study

Jiaolin Zhou, Changxi Wang, Guole Lin et al. · Clinical Cancer Research · 2020 · 136 citations

Medicine, Oncology, Gastrointestinal Oncology +16

Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study

Astrid Breitschaft, Ke Hu, Karina Hermosillo Reséndiz et al. · Diabetes Research and Clinical Practice · 2013 · 112 citations

Medicine, Endocrinology, Pharmacotherapy +11